



ASX ANNOUNCEMENT

Actinogen Presentation and Planned Conference Call

Sydney, 15 October 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to advise that Dr. Bill Ketelbey, CEO and MD of Actinogen, will provide an update on the clinical development plans for Xanamem during a conference call **on Monday, 19 October 2020 at 11:00am (AEDT)**. Dr. Ketelbey will provide an overview of the new indication in Fragile X syndrome, the planned Alzheimer's disease and Fragile X syndrome phase II clinical trials, and the capital raising to support the Alzheimer's trial.

The investor presentation is attached to this announcement and will be available on the webcast.

Participants are invited to register for the webcast using the link below. Upon registration, participants will receive a unique pin granting fast-track access to the conference call. Questions may be submitted prior to the conference call through this facility, and further questions accepted on the day.

Pre-register here: <https://s1.c-conf.com/DiamondPass/10010450-pH45r6.html>


If you are unable to register for the webcast, please call one of the numbers below prior to the start of the event and quote the following Conference ID: **10010450**.

Australia Local:	02 9007 8048	Singapore Toll Free:	800 101 2702
Australia Toll Free:	1800 908 299	Malaysia Toll Free:	1800 816 441
New Zealand Toll Free:	0800 452 795	Hong Kong Toll Free:	800 968 273
USA / Canada Toll Free:	1 855 624 0077	United Kingdom Toll Free:	0800 051 1453

A recording of the conference call will be uploaded on Actinogen's website when available.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor Enquiries

Miranda Newnham
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological, psychiatric and metabolic diseases associated with chronically elevated cortisol. The company is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer's disease, fragile X syndrome, schizophrenia and diabetes. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms. The 11β-HSD1 enzyme is particularly highly concentrated in the hippocampus and frontal cortex, areas of the brain impacted by a number of diseases and disorders, including Alzheimer's disease, fragile X syndrome, schizophrenia, diabetes and other conditions associated with chronically raised cortisol.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, confirmed the drug's safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition over placebo, which, along with other recently generated data, confirms 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment associated with raised cortisol.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021, including MCI due to Alzheimer's disease, and Fragile X Syndrome.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Xanamem™ is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.